Navigation Links
Chagatest ELISA recombinante V 3.0

ProductsChagatest ELISA recombinante V 3.0
Company Wiener Lab
Item Chagatest ELISA recombinante V 3.0
Features 
  • 1, 2 and 30 antigens specially detect antibodies in chronic patients.
  • 13 and 36 antigens detect antibodies in sera both from acute and chronic patients.
  • The recombinant technology make available the use of proteins that are only expressed in the tripomastigote form of the parasite.
Description This new kit uses proteins produced with recombinant technology, that have been fully prove throughout Latin America, and which are capable of detecting the different types of T.cruzi that exist in this area. They are proteins with amino acid sequences repeated in tandem. SAPA (shed acute phase antigen) antigen. During the acute phase of the infection, it reacts with 93% of the patients' sera. It comes from the tripomastigote.
Info Wiener Lab
Customer Service: 54-341-432 9191/9196
Web site: http://www.wiener-lab.com.ar/en/index.html

Related medicine products :

1. Chagatest ELISA
2. Microplate ELISA Washers - Manual Microplate Washer
3. Microplate ELISA Washers - Automated Microplate Washer
4. Vitamin D 25-Hydroxy ELISA 026-AC-57F1 Bone and Mineral Metabolism
5. RELISA ANA Screening System
6. BioCheck hCG ELISA
7. Human Chorionic Gonadotropin (HCG) ELISA Kit
8. Human PSA ELISA Kit
9. Total PSA ELISA Test
10. Free PSA ELISA
11. PAP Microwell ELISA
... Protects the skin over extended wearing ... barrier is the barrier of choice ... added benefit of it being discreet ... Security and confidence assured with internal ...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Medicine Products:
(Date:4/28/2017)... Mateo, CA (PRWEB) , ... April 28, 2017 , ... ... Area cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce ... allow interested persons to bookmark and read organized content on topics such as home ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to create ... by the continuing support of the Jane and Leonard Korman Family Foundation. The ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... Gasby the 2017 Public Leadership in Neurology Award (PLINA). The couple joins a ... Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox and former U.S. ...
(Date:4/27/2017)... Malibu, CA (PRWEB) , ... April 27, 2017 , ... ... United States with an oil many times purer and more potent than the market ... mountain air of Gstaad, Switzerland, as well as a patented chromatography process for extraction, ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... today released the podcast, “Make Plans for MACRA,” highlighting the impact ... the physician's office and how physicians and other clinicians are reimbursed for the ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: